AU2017222399B2 - Mass spectrometry kit - Google Patents

Mass spectrometry kit Download PDF

Info

Publication number
AU2017222399B2
AU2017222399B2 AU2017222399A AU2017222399A AU2017222399B2 AU 2017222399 B2 AU2017222399 B2 AU 2017222399B2 AU 2017222399 A AU2017222399 A AU 2017222399A AU 2017222399 A AU2017222399 A AU 2017222399A AU 2017222399 B2 AU2017222399 B2 AU 2017222399B2
Authority
AU
Australia
Prior art keywords
immunoglobulin
fragment
antibody
sample
cross
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017222399A
Other languages
English (en)
Other versions
AU2017222399A1 (en
Inventor
Jamie ASHBY
David R. Barnidge
Stephen Harding
John Mills
David L. Murray
Gregg Wallis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Binding Site Group Ltd
Mayo Clinic in Florida
Original Assignee
Binding Site Group Ltd
Mayo Foundation for Medical Education and Research
Mayo Clinic in Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806928&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2017222399(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Binding Site Group Ltd, Mayo Foundation for Medical Education and Research, Mayo Clinic in Florida filed Critical Binding Site Group Ltd
Publication of AU2017222399A1 publication Critical patent/AU2017222399A1/en
Application granted granted Critical
Publication of AU2017222399B2 publication Critical patent/AU2017222399B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/34—Purifying; Cleaning
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/62—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosols; by investigating electric discharges, e.g. emission of cathode
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Electrochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Sampling And Sample Adjustment (AREA)
AU2017222399A 2016-02-25 2017-02-24 Mass spectrometry kit Active AU2017222399B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1603291.4 2016-02-25
GBGB1603291.4A GB201603291D0 (en) 2016-02-25 2016-02-25 Antibodies
US201662368606P 2016-07-29 2016-07-29
US62/368,606 2016-07-29
PCT/GB2017/050489 WO2017144900A1 (en) 2016-02-25 2017-02-24 Mass spectrometry kit

Publications (2)

Publication Number Publication Date
AU2017222399A1 AU2017222399A1 (en) 2018-08-30
AU2017222399B2 true AU2017222399B2 (en) 2024-03-14

Family

ID=55806928

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017222399A Active AU2017222399B2 (en) 2016-02-25 2017-02-24 Mass spectrometry kit

Country Status (12)

Country Link
US (1) US12461108B2 (enExample)
EP (2) EP4123308A1 (enExample)
JP (3) JP7246927B2 (enExample)
KR (1) KR102851057B1 (enExample)
CN (2) CN116148479A (enExample)
AU (1) AU2017222399B2 (enExample)
BR (1) BR112018067435A2 (enExample)
CA (1) CA3015296A1 (enExample)
DK (1) DK3420361T3 (enExample)
ES (1) ES2936783T3 (enExample)
GB (1) GB201603291D0 (enExample)
WO (1) WO2017144900A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201708262D0 (en) 2017-05-23 2017-07-05 Binding Site Group Ltd Assay for plasma cell associated disease
SG11202108033TA (en) * 2019-01-31 2021-08-30 Regeneron Pharma Native microfluidic ce-ms analysis of antibody charge heterogeneity
CN110009008B (zh) * 2019-03-18 2020-11-06 四川大学 基于提取的免疫固定电泳图特征对其进行自动分类的方法
GB201906599D0 (en) 2019-05-10 2019-06-26 Binding Site Group Ltd Mass spectrometry calibrator
CN113811772B (zh) * 2019-05-10 2024-12-06 结合点集团有限公司 质谱分析校准物
GB201915946D0 (en) 2019-11-01 2019-12-18 Binding Site Group Ltd Quantitation of immunoglobulins i n mass spectrometry
GB202007047D0 (en) * 2020-05-13 2020-06-24 Binding Site Group Ltd Mass spectrometry controls
GB202008887D0 (en) * 2020-06-11 2020-07-29 Binding Site Group Ltd A method of identifying or characterising an immune response in a subject
GB202016822D0 (en) 2020-10-23 2020-12-09 Binding Site Group Ltd Quantitation of immunoglobulins in mass spectrometry
CN113720900A (zh) * 2021-09-14 2021-11-30 首都医科大学附属北京朝阳医院 一种基于madli-tof ms技术检测血清中m蛋白的方法
CN114324557B (zh) * 2021-12-03 2024-05-10 融智生物科技（青岛）有限公司 一种基于MALDI-TOF MS的ζ-珠蛋白的检测方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006099481A2 (en) * 2005-03-14 2006-09-21 Medimmune, Inc. Macromolecules comprising a thioether cross-link
WO2015154052A1 (en) * 2014-04-04 2015-10-08 Mayo Foundation For Medical Education And Research Isotyping immunoglobulins using accurate molecular mass

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6290090A (en) 1989-08-29 1991-04-08 University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
WO1991006570A1 (en) * 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
WO1992022653A1 (en) * 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
ATE294959T1 (de) * 1994-05-13 2005-05-15 Miltenyi Biotec Gmbh An protein gebundene sterile und pyrogenfreie säulen zum binden und entfernen von substanzen aus blut
JP2826965B2 (ja) * 1995-01-12 1998-11-18 オリエンタル酵母工業株式会社 免疫吸着体とその製造法
DE69634092T2 (de) 1995-11-03 2005-12-08 The Binding Site Ltd. Herstellung von antikörpern
US6207370B1 (en) * 1997-09-02 2001-03-27 Sequenom, Inc. Diagnostics based on mass spectrometric detection of translated target polypeptides
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
KR20070007253A (ko) * 2003-10-08 2007-01-15 이바이오사이언스 천연 면역글로불린 결합 물질 및 이의 제조 방법 및 사용방법
DE602006020850D1 (de) 2005-04-12 2011-05-05 Akira Matsumori Biomarker zur diagnose einer herzerkrankung sowie verwendung davon
US7893616B2 (en) * 2006-02-27 2011-02-22 Ohio State University Process to determine enzyme activity
WO2008079914A1 (en) 2006-12-21 2008-07-03 Novartis Ag Antibody quantitation
RU2012118620A (ru) 2009-10-09 2013-11-20 Симфоген А/С Множественное количественное определение в смеси индивидуальных рекомбинантных белков посредством сигнатурных пептидов и масс-спектрометрии
GB201001946D0 (en) 2010-02-05 2010-03-24 Binding Site Group The Ltd Cancer prognostic assay
GB2478520A (en) 2010-03-02 2011-09-14 Binding Site Group Ltd Kidney prognostic assay
GB201117172D0 (en) 2011-10-05 2011-11-16 Binding Site Group The Ltd Diabetes
GB201121265D0 (en) 2011-12-12 2012-01-18 Binding Site Group The Ltd Assay
US20150031861A1 (en) 2012-03-09 2015-01-29 Ucl Business Plc Chemical Modification of Antibodies
WO2014121031A1 (en) 2013-01-31 2014-08-07 Excelimmune, Inc. Characterization of antibody mixtures by mass spectrometry
WO2015131169A2 (en) * 2014-02-28 2015-09-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Personalized myeloma detection
US10690676B2 (en) * 2014-07-29 2020-06-23 Mayo Roundation for Medical Education and Research Quantifying monoclonal antibody therapeutics by LC-MS/MS
AU2015334455B2 (en) * 2014-10-21 2020-05-21 Gennova Biopharmaceuticals Limited A novel purification process for isolation and commercial production of recombinant TNK-tPA (Tenecteplase)
US11209439B2 (en) 2015-09-24 2021-12-28 Mayo Foundation For Medical Education And Research Identification of immunoglobulin free light chains by mass spectrometry

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006099481A2 (en) * 2005-03-14 2006-09-21 Medimmune, Inc. Macromolecules comprising a thioether cross-link
WO2015154052A1 (en) * 2014-04-04 2015-10-08 Mayo Foundation For Medical Education And Research Isotyping immunoglobulins using accurate molecular mass

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GOLDBERG, M. ET AL: "Specific Interchain Cross-Linking of Antibodies Using Bismaleimides. Repression of Ligand Leakage in Immunoaffinity Chromatography", BIOCONJUGATE CHEM. 1991, vol. 2, pages 275 - 280 *

Also Published As

Publication number Publication date
AU2017222399A1 (en) 2018-08-30
JP7541045B2 (ja) 2024-08-27
CN108885218A (zh) 2018-11-23
KR20180132651A (ko) 2018-12-12
GB201603291D0 (en) 2016-04-13
EP3420361B1 (en) 2023-01-04
US20190094239A1 (en) 2019-03-28
JP7246927B2 (ja) 2023-03-28
CN116148479A (zh) 2023-05-23
US12461108B2 (en) 2025-11-04
BR112018067435A2 (pt) 2019-01-02
JP2019509483A (ja) 2019-04-04
EP3420361A1 (en) 2019-01-02
EP4123308A1 (en) 2023-01-25
JP2023033281A (ja) 2023-03-10
DK3420361T3 (da) 2023-01-23
WO2017144900A1 (en) 2017-08-31
JP7541070B2 (ja) 2024-08-27
KR102851057B1 (ko) 2025-08-28
ES2936783T3 (es) 2023-03-22
JP2022069446A (ja) 2022-05-11
CA3015296A1 (en) 2017-08-31

Similar Documents

Publication Publication Date Title
AU2017222399B2 (en) Mass spectrometry kit
US20230080943A1 (en) Assay for plasma cell associated disease
US20190048064A1 (en) Antibodies
HK40087264A (en) Mass spectrometry kit
HK40081916A (en) Assay for plasma cell associated disease
KR20230029629A (ko) 질량 분석법 컨트롤

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ MASS SPECTROMETRY KIT